Research on HIV epidemiology and control. Covers prevention policy, HIV-substance use links, TB co-treatment, and clearing infection in newborns.
Researchers found that the human gut stores a significant amount of HIV, equivalent to nearly twice the amount in the bloodstream. The gut's role in harboring the virus was not fully understood until now.
Researchers from the Université de Montréal have identified a defect in the immune response to HIV and found a way to correct it. The team successfully stimulated a protein that prevents the virus from making immune system cells dysfunctional, opening new prospects for therapeutic strategies.
Health development agencies contribute to insufficient public health budgets by requiring host countries to fund interventions sustainably. Public health budgets increase with stronger national and international financial commitments, improving healthcare capacity within host countries.
The International AIDS Society guidelines recommend treating HIV patients with an undetectable viral load using a combination of FUZEON and protease inhibitors. This approach is supported by recent clinical trials and has been endorsed by various health organizations, aiming to combat drug resistance and improve treatment outcomes.
A massive scale-up of HIV/AIDS treatment programs in Zambia showed favorable patient outcomes, demonstrating the feasibility of expansion in sub-Saharan Africa. The program's success was attributed to leadership and advocacy by the Zambian government, strict protocols for patient care, and large financial resources.
The study found that the efavirenz plus two-NRTI regimen was significantly more effective at reducing HIV viral load in the blood. A second approach, lopinavir/ritonavir, also performed well and may be a viable alternative for patients who experience intolerable side effects from NRTIs. The trial included 753 participants and showed su...
Researchers at Indiana University are working on a project to craft messages that encourage women to be tested for HIV and enroll in research clinical studies. The study aims to identify barriers to testing and develop persuasive messages to overcome them.
A new CD-ROM containing more than 40 selected chapters from the HIV InSite Knowledge Base is being released to provide comprehensive HIV information in the developing world. The disk features a wide range of topics, including natural science, diagnosis and clinical management, transmission and prevention.
A culturally tailored HIV-prevention program reduces risky sexual behaviors among Latino adolescents, even a year after attendance. The study demonstrates the effectiveness of behavioral training in decreasing HIV transmission risk.
A tailored HIV prevention program was found to decrease risky sexual behavior among Latino adolescents, increasing condom use and abstinence. The program incorporated aspects of Latino culture into sexual health education messages, resulting in significant reductions in unprotected sex and multiple partners.
Stopping HIV treatment temporarily can decrease side effects and expenses, however it might cause the disease to progress faster. Researchers discovered that interrupting treatment for certain periods of time was as effective as continuous therapy in controlling the virus.
The Heineken Workplace Programme, which provides antiretroviral treatment to employees, shows that offering HAART is feasible. By restricting treatment options, companies can manage HIV patients while prioritizing the health of their workforce.
A Purdue University researcher has developed a molecule that can effectively combat drug-resistant strains of HIV, the virus that causes AIDS. The FDA recently approved the pill-based therapy, known as Darunavir, which is expected to be available to physicians this year.
Researchers discovered that HIV's surface glycoprotein interacts with CXCR4 on uninfected CD4+ T cells, triggering autophagy. This interaction leads to the death of uninfected bystander cells, contributing to the depletion of immune system cells in AIDS patients.
Dr. Joe Sodroski, a renowned HIV researcher, received the 2006 Retrovirology Prize for his significant contributions to understanding HIV infection and disease. He made key discoveries about how HIV infects cells and causes disease, including identifying the Rev gene and producing the first X-ray structure of gp120.
Global Plan to Stop TB 2006-2015 aims to increase joint TB/HIV programs, benefiting 3 million co-infected with antiretrovirals. Tuberculosis is a leading killer of people living with HIV, and collaboration between communities and governments is crucial to access effective interventions.
The Indian government's plan for controlling HIV is not yet fully implemented, and the consequences could be devastating. Experts call for increased access to care and treatment services, as well as strategic knowledge building, to mitigate the social fallout of the epidemic.
A study of 18 HIV-positive subjects reveals that HIV in the brain and central nervous system is genetically different from HIV in the blood. A particular mutation in the HIV envelope gene is correlated with cognitive impairment, suggesting a key to understanding and potentially treating HIV dementia.
A cross-sectional study of 1,268 adults in Botswana found that routine HIV testing is widely accepted and may reduce barriers to testing. The authors emphasize the importance of informed consent and human rights safeguards to protect individuals from discrimination and violence related to testing.
A study of 38 infant-mother pairs found that women who transmitted HIV to their babies had lower levels of a neutralizing antibody, suggesting its potential as a protective factor. The study suggests further research into the antibody's role could lead to an effective vaccine or passive antibody approaches.
A randomized trial in Zimbabwe found that providing HIV testing at the workplace significantly increases uptake of voluntary counselling and testing. The study suggests that this approach could improve HIV testing rates in Africa, and that intermittent provision might be as effective as continuous testing.
A comprehensive training plan is needed to deliver HIV medicines to patients in poor countries. The authors suggest research is required to define the best approach, including the implementation of such programs.
A study found that only 15% of adolescent sexual assault survivors completed the full 28-day course of antiviral medications, highlighting difficulties in prescribing therapies to this population. The lack of adherence is attributed to factors such as unclear risk assessment and psychiatric conditions.
The University of Pittsburgh-affiliated Magee-Womens Research Institute has been selected to lead international HIV/AIDS prevention and treatment efforts. The institute will focus on developing microbicides to prevent HIV transmission, particularly among women and their partners.
A recent study in Zambia found that abstinence messages were not enough to prevent HIV infection among unmarried women aged 13-20. Women from more conservative denominations abstained longer and had lower rates of condom use during first sex, highlighting the need for targeted prevention strategies.
A new international collaboration aims to identify genetic variations that affect the body's response to HIV. By analyzing patient cohorts from nine countries, researchers hope to pinpoint common genes influencing the disease progression and develop a vaccine targeting these responses.
A study found that HIV-positive mothers-to-be are at a higher risk of developing anaemia, pregnancy-induced hypertension, and other health issues. Women with HIV also received less antenatal care and experienced lower birth weights, highlighting the need for better guidance on managing pregnant women with HIV.
A new study found that HIV infection rates among young non-Hispanic blacks are significantly higher than other racial groups, with a rate of 4.9 per 1,000 compared to 0.22 for all other races. The study suggests that segregation and differences in sexual networks contribute to the disparity.
Advances in HIV care have yielded a total survival benefit of 2.8 million years in the US, saving an additional 137,000 years of life through mother-to-child transmission prevention. The study found that HIV therapies have transformed the disease from a rapidly fatal condition to a controllable one.
The Infectious Diseases Society of America calls for routine HIV testing to identify those who need treatment. Early testing and connection with care can save millions more lives beyond the three million already saved through antiretroviral therapy.
Researchers at FSU have produced high-resolution images of the HIV virus, revealing its complex molecular surface architecture and enabling the development of more effective vaccines. The study, published in Nature, provides valuable insights into the virus's structure and behavior, which could lead to breakthroughs in vaccine design.
A recent study published in AIDS Education and Prevention found that few HIV-positive gay men regret sharing their diagnosis with friends and family. In fact, only 4.2% of participants reported regret after disclosing their status to at least one social network member.
A study found that patients with HIV-HBV coinfection can successfully undergo liver transplantation without progression of viral disease, even in the setting of lamivudine resistance. Controlling HBV is crucial for survival, and ongoing monitoring will be essential to minimize liver-related complications.
A new study will develop a cohort of 1,000 HIV-infected IDUs with a history of injection drug use to examine treatment access and adherence. The research aims to improve access to life-saving HIV and HCV treatments for marginalized individuals in Vancouver's Downtown Eastside.
A study assessing combined interventions found co-trimoxazole, ART, and insecticide-treated bed nets substantially reduced malaria frequency in HIV-infected adults. The treatments had a cumulative protective effect on malaria incidence, with co-trimoxazole lowering rates by 76%, ART and co-trimoxazole by 92%, and all three by 95%.
Researchers will investigate whether liver damage in HIV patients with hepatitis C is caused by the medication or the virus itself. The goal of the study is to improve treatment outcomes for patients with both conditions.
The US government's PEPFAR program aims to prevent 7 million new HIV infections by 2010, but a GAO report reveals that an ambiguous approach to condom promotion may hinder its success. Promoting condoms alongside abstinence and faithfulness messages is crucial for reaching this target.
A new study by Johns Hopkins Medicine researchers suggests that a commercially available antibiotic, ceftriaxone, may be effective in fighting dementia in HIV patients. The study found that ceftriaxone protected human neuronal cells from the effects of HIV proteins Tat and gp120.
A University of Toronto study found HIV infection rates declining in South India, likely due to increased condom use and awareness programs. The study tracked data from antenatal clinics, showing a significant decrease in new infections among young adults.
TB researchers hope to find novel ways of killing the organism using a protective protein called heme oxygenase 1. The project aims to pinpoint the role of alcoholism in the global epidemic by studying HIV- and tuberculosis-infected patients in India.
A study published in Archives of Dermatology found that injecting polylactic acid can safely and effectively treat facial lipoatrophy in HIV patients, improving skin and fat thickness over 12 months. The treatment showed significant results, with increased dermal thickness persisting beyond the initial six injections.
Two DNA repair proteins, XPB and XPD, can destroy HIV DNA, reducing viral replication and integration into host chromosomes. This finding may lead to new strategies for treating HIV infection and AIDS.
Scientists have discovered a way to increase HIV-1 p24 protein production in plants using antibody-antigen fusion molecules, potentially leading to cheaper and more effective vaccines. This technology could also pave the way for mass-producing plant-derived pharmaceuticals for poor populations in developing countries.
Researchers found combined therapy improved survival rates for patients with AIDS-related lymphoma, comparable to non-HIV patients with lymphoma treated with CHOP. For standard-risk ARL patients, 79% achieved complete remission and 50% survived after 47 months.
A study analyzing healthcare utilization data for HIV-infected patients found that HAART is cost-effective as long as patients stick to treatment. However, the study also revealed significant disparities in healthcare costs between healthier and sicker patients, highlighting inadequate reimbursement to treating physicians and clinics.
A study by University of Illinois Chicago found that mothers teaching their daughters about HIV and sexual health can significantly reduce high-risk behavior. The Mother/Daughter HIV Risk Reduction program, which included joint mother/daughter homework assignments and abstinence agreements, was more effective than other interventions.
Researchers found a significant decline in HIV prevalence in some groups, with a 49% drop for women aged 15-24 and a 23% drop for men aged 17-29. Behavioral changes, including delayed sex and fewer casual partners, are believed to be the main reason for this decline.
A Duke University Medical Center study found that free HIV tests are more cost-effective in preventing infections, drawing in three times as many people for testing. The research showed that the cost of prevention dropped from $170 to $92 per person when testing rates increased.
The study found that non-nucleoside reverse transcriptase inhibitor (NNRTI)-resistant viruses have an advantage over sensitive viruses even at low levels of adherence. NNRTI and protease inhibitors are potent antiretroviral drugs with demonstrated effectiveness when taken as directed.
A new HIV vaccine strategy involves removing the natural immune system's 'brake' to enhance anti-HIV responses, showing promise for improved treatment and prevention. The approach uses a molecule called SOCS1 to regulate immune cells and boost antibody and T-cell responses.
Researchers have discovered a novel strategy for enhancing HIV vaccination by silencing the SOCS1 molecule in dendritic cells, which can induce a good memory immune response and boost the potency of HIV DNA vaccination. This approach has potential for therapeutic and prophylactic vaccines against HIV and other pathogens.
A study found that adolescent daughters of parents with HIV have a high childbearing rate, with 38-67% experiencing pregnancy. Interventions like family-based counseling and academic support reduced the likelihood of early childbearing.
The Children's Hospital of Philadelphia has received a four-year, $6.7 million grant to study novel HIV therapy targeting neurokinin-1 receptors. The program aims to block the virus from immune cells, improve innate immune function, and reduce symptoms of depression associated with the disease.
Research examines how drug policy affects incarceration rates and HIV infection levels among African Americans, who make up 40% of those incarcerated and 50% of new HIV diagnoses. The study calls for further research on the corrections system's impact on HIV risk and recommends investigating specific components of drug policy.
A pilot study finds that a jewelry-making program significantly reduces HIV risk and increases self-esteem among Baltimore women involved in prostitution. The program also generates income through public sales, with participants earning over $7,000.
Researchers at the University of Pennsylvania School of Medicine have discovered a human DNA-associated protein called LEDGF that controls where HIV integrates into human chromosomes. This finding has significant implications for improving the design of gene-therapy delivery systems.
A study of over 3,900 children with HIV found that total lymphocyte count can predict disease progression as well as CD4 cell percentage. The current WHO guidelines for starting ART are inconsistent and may lead to inadequate treatment in low-income countries.
Researchers found a link between placental microtransfusions and HIV transmission in mothers, particularly during vaginal delivery. The study suggests that better understanding of microtransfusions could lead to more effective treatments for preventing mother-to-child transmission of HIV.
A recent study found that 76% of treatment-experienced patients would consider using a self-injectable HIV therapy if recommended by their physician. Despite this, only one quarter of eligible patients have discussed the option with their doctors, highlighting a significant barrier to adoption.
Researchers found that HAART can reduce the risk of tuberculosis in HIV patients, but not eliminate it. Patients who are immunodeficient or exposed to TB in a hospital setting are at increased risk of developing active TB.